The alliance will be focused on going together with Cubist’s drug discovery programs with new lead compounds in the development of new anti-bacterial drugs. Fundacion MEDINA scientific director
Further details on the partnership were kept confidential. Avid Bioservices president Steven King said, "We are pleased to be working with Phage to offer their proprietary expression system,
The collaboration aims at offering joint services for the expression of recombinant proteins with site-specific modification and labeling, such as PEGylation for half-life extension of proteins. Almac developed
The study of 3,883 patients, with secondary hyperparathyroidism (HPT) and chronic kidney disease (CKD) receiving dialysis, evaluated Sensipar/Mimpara (cinacalcet) for the reduction of the risk of mortality and
The FDA approval of Elelyso for the treatment of type 1 Gaucher disease has triggered the payment. Pfizer and Protalix signed an exclusive license and supply agreement relating
Dako’s HercepTest and HER2 FISH pharmDx Kit are used to recognise cancer patients with HER2-positive metastatic breast cancer, who may be eligible for Perjeta treatment. Pertuzumab, which received
The solution deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I – Phase IV drug and devices studies in many languages across the world. POI
knomeclinic when upgraded to Early Access Program will have a robust, scalable, and extensible informatics and annotation platform,zkGAP, Desktop interpretation-support application, Knowledge database and Curation applications. Knome chief
The approval is based on a Phase III study in which combination of Perjeta, Herceptin and chemotherapy demonstrated a significant improvement in PFS compared to Herceptin plus chemotherapy
The purpose of the commercial royalty-bearing license is to conduct a larger scale market evaluation. The licensee has agreed to rental and royalty terms allowing them to install
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.